Financing tomorrow’s breakthrough innovations
Alta Partners is a leading venture capital firm in life sciences, funding over 145 companies in the industry since 1996. Our diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for our companies and our investors.
Intersouth Partners is one of the most active and experienced venture capital firms in the Southeast, having invested in more than 100 private companies. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast.
For more than 30 years InterWest has partnered with exceptional entrepreneurs to build winning technology and healthcare companies. With more than 200 years of combined operating and investing experience, InterWest has raised $2.8 billion, completed more than 70 IPOs, and participated in 60 upside acquisitions.
Since 2002, MedImmune Ventures has been fostering innovation and entrepreneurship by investing in emerging healthcare companies. Originally established by the founders of MedImmune, MedImmune Ventures is seeking today to deliver superior financial returns by investing in private biopharmaceutical, medical technology and healthcare IT companies across therapeutic areas and geographies. Our investment philosophy is to partner with management teams to advance cutting-edge science and develop novel therapies for patients in need.
Osage University Partners
Osage University Partners is a venture capital fund that invests in spinouts from a network of over 45 affiliated universities and research institutions. Osage University Partners invests across all sectors of university commercialization, including Information Technology, Energy, Materials, and Life Science. Osage University Partners is a passive investor that participates in top tier venture capital syndicates investing in companies at all stages of development.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Our current portfolio includes approximately 30 private and public companies and since our founding in 1985, we have invested over $680MM in the biotech space.